CDT Advances Myeloperoxidase Inhibitor AZD5904 into Global Patent Phase for Male Infertility Treatment
Key Insights
CDT Equity Inc. (search) has advanced AZD5904, a myeloperoxidase (search) inhibitor originally licensed from AstraZeneca, into the Patent Cooperation Treaty phase for global intellectual property protection.
The compound has demonstrated a favorable safety profile across five Phase 1 studies involving 181 subjects, with no overtly drug-related adverse events identified.
CDT is actively seeking strategic partnerships to advance AZD5904 for idiopathic male infertility (search) and oncology-associated infertility (search) indications, representing significant unmet medical needs.
CDT Equity Inc. (search) announced that AZD5904, a potent inhibitor of human myeloperoxidase (search) originally licensed from AstraZeneca, has progressed into the Patent Cooperation Treaty (PCT) phase, marking a significant milestone in the globalization of its intellectual property protection. The company is now actively pursuing strategic partnerships to advance the compound into later-stage development for male infertility applications.
Robust Clinical Safety Profile Supports Development
AZD5904 benefits from an extensive clinical safety data package, with a total of 181 subjects dosed across five Phase 1 studies. The asset has demonstrated a favorable safety profile, with no overtly drug-related adverse events identified. This level of human clinical validation, alongside the company's increasingly robust intellectual property position, significantly enhances the attractiveness of the asset for downstream development and partnering opportunities.
Intellectual Property Strategy and Global Protection
CDT holds both a composition of matter patent and a method of use patent relating to AZD5904 in idiopathic male infertility (search), supported by pre-clinical data demonstrating its therapeutic potential. The progression to PCT stage enables the company to pursue broader international protection, supporting the potential global development and commercialization of the asset.
Targeting Unmet Medical Needs in Male Infertility
The company has identified promising signals for AZD5904 in idiopathic male infertility (search), as well as in related oncology-associated infertility (search) markets. CDT believes these indications represent areas of significant unmet medical need and commercial opportunity, positioning the compound as a potentially valuable therapeutic option in underserved patient populations.
Strategic Partnering Initiative
In light of the strength of the clinical dataset, existing patent protection, and expanded global IP strategy, CDT is now actively seeking out-licensing and strategic partnering opportunities to advance AZD5904 into later-stage development. The company intends to position the asset as a data-backed, clinically de-risked opportunity for pharmaceutical partners, with the potential to generate near-term and long-term value through structured licensing arrangements.
"AZD5904 represents a highly compelling asset within our portfolio, combining human safety data, pre-clinical mechanistic validation, and a growing intellectual property position," said Dr. Joanne Holland, Chief Scientific Officer of CDT. "The transition into PCT phase allows us to take a global view on development and partnering, and we are now focused on identifying the right partner to advance this asset into its next stage."
Company Background and Strategic Focus
CDT Equity Inc. (search) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments.